Spiramycin efficacy in infectious diseases

Abstract

In recent years, interest in macrolides has expanded significantly, primarily in infectious respiratory diseases treatment and due to an increase in the frequency of infections caused by intracellular microorganisms — chlamydia, mycoplasmas, and Helicobacter pylori. The aim: to evaluate spiramycin effectiveness in treating infectious diseases and assess its benefits and side effects in people with chronic comorbidities.